Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Quidel Corp (NASDAQ: QDEL) today and set a price target of $80. The company’s shares closed on Friday at $71.85, close to its 52-week high of $77.63.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 20.0% and a 64.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Idexx Laboratories, and Exact Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quidel Corp with a $79.25 average price target, implying a 10.3% upside from current levels. In a report issued on September 5, Barclays also maintained a Buy rating on the stock with a $85 price target.
.
See today’s analyst top recommended stocks >>
Based on Quidel Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.08 million. In comparison, last year the company had a GAAP net loss of $11.84 million.
Based on the recent corporate insider activity of 97 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Kenneth Buechler, a Director at QDEL sold 5,000 shares for a total of $375,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes immunoassays, molecular diagnostics, virology, and specialty products. Immunoassay tests are for physician offices, hospital laboratories, emergency departments, pharmacies, and other urgent care or alternative site settings.